Transactivation	B:C0040624
Domain	O
of	O
Human	O
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	O
in	O
Drosophila	O
Disease	O
Models	I:C0684309
.	O

Transactivation	O
Domain	B:C1514562
of	O
Human	O
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	O
in	O
Drosophila	O
Disease	O
Models	I:C0684309
.	O

Transactivation	O
Domain	O
of	O
Human	B:C1454487
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	O
in	O
Drosophila	O
Disease	O
Models	I:C0684309
.	O

Transactivation	O
Domain	O
of	O
Human	O
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	O
in	O
Drosophila	O
Disease	O
Models	I:C0684309
.	O

Transactivation	O
Domain	O
of	O
Human	O
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	B:C0235032
in	O
Drosophila	O
Disease	O
Models	I:C0684309
.	O

Transactivation	O
Domain	O
of	O
Human	O
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	O
in	O
Drosophila	B:C0013138
Disease	O
Models	I:C0684309
.	O

Transactivation	O
Domain	O
of	O
Human	O
c	I:C1454487
-	I:C1454487
Myc	I:C1454487
Is	O
Essential	O
to	O
Alleviate	O
Poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
Mediated	O
Neurotoxicity	O
in	O
Drosophila	O
Disease	B:C0684309
Models	I:C0684309
.	O

Polyglutamine	B:C0384782
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	B:C0012634
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	B:C0087012
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	B:C0027765
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	B:C0205229
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	B:C0079941
region	I:C0079941
of	O
the	O
affected	O
gene	O
.	O

Polyglutamine	O
(	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
)	O
disorders	O
,	O
such	O
as	O
Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
and	O
spinocerebellar	O
ataxias	I:C0087012
,	O
represent	O
a	O
group	O
of	O
neurological	O
disorders	I:C0027765
which	O
arise	O
due	O
to	O
an	O
atypically	O
expanded	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
tract	O
in	O
the	O
coding	O
region	I:C0079941
of	O
the	O
affected	O
gene	B:C0017337
.	O

Pathogenesis	B:C0699748
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	B:C0012634
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	B:C0007634
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	B:C1564139
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	B:C0007637
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	B:C0007637
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	B:C0007634
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	B:C0040648
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	B:C0033684
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	B:C0027882
dysfunction	O
and	O
apoptosis	O
.	O

Pathogenesis	O
of	O
these	O
disorders	O
inside	O
the	O
cells	O
begins	O
with	O
the	O
assembly	O
of	O
these	O
mutant	O
proteins	I:C1564139
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
bodies	I:C0007637
(	O
inclusion	O
bodies	I:C0007637
)	O
,	O
which	O
progressively	O
sequester	O
several	O
vital	O
cellular	O
transcription	O
factors	I:C0040648
and	O
other	O
essential	O
proteins	O
,	O
and	O
finally	O
leads	O
to	O
neuronal	O
dysfunction	O
and	O
apoptosis	B:C0162638
.	O

We	O
have	O
shown	O
earlier	O
that	O
targeted	O
upregulation	B:C0041904
of	O
Drosophila	O
myc	I:C1317967
(	O
Drosophila	O
myc	I:C1317967
)	O
dominantly	O
suppresses	O
the	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
toxicity	O
in	O
Drosophila	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
targeted	O
upregulation	O
of	O
Drosophila	B:C1317967
myc	I:C1317967
(	O
Drosophila	O
myc	I:C1317967
)	O
dominantly	O
suppresses	O
the	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
toxicity	O
in	O
Drosophila	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
targeted	O
upregulation	O
of	O
Drosophila	O
myc	I:C1317967
(	O
Drosophila	B:C1317967
myc	I:C1317967
)	O
dominantly	O
suppresses	O
the	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
toxicity	O
in	O
Drosophila	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
targeted	O
upregulation	O
of	O
Drosophila	O
myc	I:C1317967
(	O
Drosophila	O
myc	I:C1317967
)	O
dominantly	O
suppresses	O
the	O
poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
toxicity	O
in	O
Drosophila	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
targeted	O
upregulation	O
of	O
Drosophila	O
myc	I:C1317967
(	O
Drosophila	O
myc	I:C1317967
)	O
dominantly	O
suppresses	O
the	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
toxicity	B:C0600688
in	O
Drosophila	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
targeted	O
upregulation	O
of	O
Drosophila	O
myc	I:C1317967
(	O
Drosophila	O
myc	I:C1317967
)	O
dominantly	O
suppresses	O
the	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
toxicity	O
in	O
Drosophila	B:C0013138
.	O

The	O
present	O
study	O
examines	O
the	O
ability	O
of	O
the	O
human	B:C1454487
c-myc	I:C1454487
proto	I:C1454487
-	I:C1454487
oncogene	I:C1454487
and	O
also	O
identifies	O
the	O
specific	O
c	O
-	I:C1454487
Myc	I:C1454487
isoform	O
which	O
drives	O
the	O
mitigation	O
of	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
,	O
so	O
that	O
it	O
could	O
be	O
further	O
substantiated	O
as	O
a	O
potential	O
drug	O
target	O
.	O

The	O
present	O
study	O
examines	O
the	O
ability	O
of	O
the	O
human	O
c-myc	I:C1454487
proto	I:C1454487
-	I:C1454487
oncogene	I:C1454487
and	O
also	O
identifies	O
the	O
specific	O
c	B:C1454487
-	I:C1454487
Myc	I:C1454487
isoform	O
which	O
drives	O
the	O
mitigation	O
of	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
,	O
so	O
that	O
it	O
could	O
be	O
further	O
substantiated	O
as	O
a	O
potential	O
drug	O
target	O
.	O

The	O
present	O
study	O
examines	O
the	O
ability	O
of	O
the	O
human	O
c-myc	I:C1454487
proto	I:C1454487
-	I:C1454487
oncogene	I:C1454487
and	O
also	O
identifies	O
the	O
specific	O
c	O
-	I:C1454487
Myc	I:C1454487
isoform	B:C0597298
which	O
drives	O
the	O
mitigation	O
of	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
,	O
so	O
that	O
it	O
could	O
be	O
further	O
substantiated	O
as	O
a	O
potential	O
drug	O
target	O
.	O

The	O
present	O
study	O
examines	O
the	O
ability	O
of	O
the	O
human	O
c-myc	I:C1454487
proto	I:C1454487
-	I:C1454487
oncogene	I:C1454487
and	O
also	O
identifies	O
the	O
specific	O
c	O
-	I:C1454487
Myc	I:C1454487
isoform	O
which	O
drives	O
the	O
mitigation	O
of	O
poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
,	O
so	O
that	O
it	O
could	O
be	O
further	O
substantiated	O
as	O
a	O
potential	O
drug	O
target	O
.	O

The	O
present	O
study	O
examines	O
the	O
ability	O
of	O
the	O
human	O
c-myc	I:C1454487
proto	I:C1454487
-	I:C1454487
oncogene	I:C1454487
and	O
also	O
identifies	O
the	O
specific	O
c	O
-	I:C1454487
Myc	I:C1454487
isoform	O
which	O
drives	O
the	O
mitigation	O
of	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	B:C0235032
,	O
so	O
that	O
it	O
could	O
be	O
further	O
substantiated	O
as	O
a	O
potential	O
drug	O
target	O
.	O

The	O
present	O
study	O
examines	O
the	O
ability	O
of	O
the	O
human	O
c-myc	I:C1454487
proto	I:C1454487
-	I:C1454487
oncogene	I:C1454487
and	O
also	O
identifies	O
the	O
specific	O
c	O
-	I:C1454487
Myc	I:C1454487
isoform	O
which	O
drives	O
the	O
mitigation	O
of	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
,	O
so	O
that	O
it	O
could	O
be	O
further	O
substantiated	O
as	O
a	O
potential	O
drug	B:C1254351
target	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
similar	O
to	O
Drosophila	B:C1317967
myc	I:C1317967
,	O
tissue	O
-	O
specific	O
induced	O
expression	I:C1171362
of	O
human	O
c-myc	I:C1454487
also	O
suppresses	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
by	O
an	O
analogous	O
mechanism	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
similar	O
to	O
Drosophila	O
myc	I:C1317967
,	O
tissue	O
-	O
specific	O
induced	B:C1171362
expression	I:C1171362
of	O
human	O
c-myc	I:C1454487
also	O
suppresses	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
by	O
an	O
analogous	O
mechanism	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
similar	O
to	O
Drosophila	O
myc	I:C1317967
,	O
tissue	O
-	O
specific	O
induced	O
expression	I:C1171362
of	O
human	B:C1454487
c-myc	I:C1454487
also	O
suppresses	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
by	O
an	O
analogous	O
mechanism	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
similar	O
to	O
Drosophila	O
myc	I:C1317967
,	O
tissue	O
-	O
specific	O
induced	O
expression	I:C1171362
of	O
human	O
c-myc	I:C1454487
also	O
suppresses	O
poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	O
by	O
an	O
analogous	O
mechanism	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
that	O
similar	O
to	O
Drosophila	O
myc	I:C1317967
,	O
tissue	O
-	O
specific	O
induced	O
expression	I:C1171362
of	O
human	O
c-myc	I:C1454487
also	O
suppresses	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
-	O
mediated	O
neurotoxicity	B:C0235032
by	O
an	O
analogous	O
mechanism	O
.	O

Among	O
the	O
three	O
isoforms	B:C0597298
of	O
c	O
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	O
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	O
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	O
which	O
lacks	O
the	O
transactivation	O
domain	O
.	O

Among	O
the	O
three	O
isoforms	O
of	O
c	B:C1454487
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	O
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	O
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	O
which	O
lacks	O
the	O
transactivation	O
domain	O
.	O

Among	O
the	O
three	O
isoforms	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	B:C1454487
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	O
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	O
which	O
lacks	O
the	O
transactivation	O
domain	O
.	O

Among	O
the	O
three	O
isoforms	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	O
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	B:C1454487
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	O
which	O
lacks	O
the	O
transactivation	O
domain	O
.	O

Among	O
the	O
three	O
isoforms	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	O
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	O
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	B:C1454487
which	O
lacks	O
the	O
transactivation	O
domain	O
.	O

Among	O
the	O
three	O
isoforms	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	O
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	O
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	O
which	O
lacks	O
the	O
transactivation	B:C0040624
domain	O
.	O

Among	O
the	O
three	O
isoforms	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
,	O
the	O
rescue	O
potential	O
was	O
maximally	O
manifested	O
by	O
the	O
full	O
-	O
length	O
c	O
-	I:C1454487
Myc2	I:C1454487
protein	I:C1454487
,	O
followed	O
by	O
c	O
-	I:C1454487
Myc1	I:C1454487
,	O
but	O
not	O
by	O
c-MycS	O
which	O
lacks	O
the	O
transactivation	O
domain	B:C1514562
.	O

Our	O
study	O
suggests	O
that	O
strategies	O
focussing	O
on	O
the	O
transactivation	B:C0040624
domain	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
could	O
be	O
a	O
very	O
useful	O
approach	O
to	O
design	O
novel	O
drug	O
molecules	I:C1254351
against	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
disorders	O
.	O

Our	O
study	O
suggests	O
that	O
strategies	O
focussing	O
on	O
the	O
transactivation	O
domain	B:C1514562
of	O
c	O
-	I:C1454487
Myc	I:C1454487
could	O
be	O
a	O
very	O
useful	O
approach	O
to	O
design	O
novel	O
drug	O
molecules	I:C1254351
against	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
disorders	O
.	O

Our	O
study	O
suggests	O
that	O
strategies	O
focussing	O
on	O
the	O
transactivation	O
domain	O
of	O
c	B:C1454487
-	I:C1454487
Myc	I:C1454487
could	O
be	O
a	O
very	O
useful	O
approach	O
to	O
design	O
novel	O
drug	O
molecules	I:C1254351
against	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
disorders	O
.	O

Our	O
study	O
suggests	O
that	O
strategies	O
focussing	O
on	O
the	O
transactivation	O
domain	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
could	O
be	O
a	O
very	O
useful	O
approach	O
to	O
design	O
novel	O
drug	B:C1254351
molecules	I:C1254351
against	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
disorders	O
.	O

Our	O
study	O
suggests	O
that	O
strategies	O
focussing	O
on	O
the	O
transactivation	O
domain	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
could	O
be	O
a	O
very	O
useful	O
approach	O
to	O
design	O
novel	O
drug	O
molecules	I:C1254351
against	O
poly	B:C0384782
(	I:C0384782
Q	I:C0384782
)	I:C0384782
disorders	O
.	O

Our	O
study	O
suggests	O
that	O
strategies	O
focussing	O
on	O
the	O
transactivation	O
domain	O
of	O
c	O
-	I:C1454487
Myc	I:C1454487
could	O
be	O
a	O
very	O
useful	O
approach	O
to	O
design	O
novel	O
drug	O
molecules	I:C1254351
against	O
poly	O
(	I:C0384782
Q	I:C0384782
)	I:C0384782
disorders	B:C0012634
.	O

